Aprepitant in multiple-day cisplatin-based chemotherapy.

e19591 Background: Aprepitant is a NK-1 inhibitor approved in combination with serotonin antagonists and dexamethasone (Dex) for highly and moderately emetogenic chemotherapy. Antiemetic regimens for multiple-day chemotherapy are not standard and guidelines recommend serotonin antagonists and Dex for each day of chemotherapy and for following days. Studies with aprepitant in that setting are ongoing. In our center, aprepitant use with multiple-day chemotherapy was prescribed at the physician’s discretion. Methods: We did a retrospective study of the use of aprepitant with cisplatin-based multiple-day chemotherapy (CBMDC) regimens from November 2008 to November 2011. Pharmacy files were used to identify patients that received at least one dose of CBMDC. Data was extracted from pharmacy and medical records. Objectives included efficacy (complete response (CR), absence of nausea and vomiting, change in antiemetics) and safety of different regimens. Results: During the study period, 39 patients (34 men) recei...